Contineum Therapeutics, Inc. Class A Common Stock CTNM
i
Market datapartial · fetched 2026-11-11T05:55:01.461Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:09.476889902Z
FundamentalsAlpha Vantage · unavailable
Contineum Therapeutics, Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.78 | 182.8% | 28.7% | |||
| 25Δ | 8.61 | 151.9% | 21.4% | |||
| 30Δ | 9.44 | 121.0% | 14.0% | |||
| 35Δ | 10.16 | 109.7% | 9.1% | |||
| 40Δ | 10.64 | 138.0% | 9.1% | |||
| 45Δ | 15.13 | 453.0% | 60.6% | 11.12 | 166.3% | 9.1% |
| 50Δ | 13.29 | 408.1% | 44.2% | 11.60 | 194.5% | 9.1% |
| 55Δ | 12.08 | 222.8% | 9.1% | |||
| 60Δ | 12.62 | 248.4% | 8.9% | |||
| 65Δ | 13.57 | 255.0% | 7.7% | |||
| 70Δ | 14.53 | 261.7% | 6.4% | |||
| 75Δ | 16.99 | 311.8% | 5.8% | |||
| 80Δ | 22.91 | 405.8% | 5.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.78
- IV
- 182.8%
- B/E move
- 28.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.61
- IV
- 151.9%
- B/E move
- 21.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.44
- IV
- 121.0%
- B/E move
- 14.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.16
- IV
- 109.7%
- B/E move
- 9.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.64
- IV
- 138.0%
- B/E move
- 9.1%
45Δ
- Pseudo strike
- 15.13
- IV
- 453.0%
- B/E move
- 60.6%
- Pseudo strike
- 11.12
- IV
- 166.3%
- B/E move
- 9.1%
50Δ
- Pseudo strike
- 13.29
- IV
- 408.1%
- B/E move
- 44.2%
- Pseudo strike
- 11.60
- IV
- 194.5%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.08
- IV
- 222.8%
- B/E move
- 9.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.62
- IV
- 248.4%
- B/E move
- 8.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.57
- IV
- 255.0%
- B/E move
- 7.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.53
- IV
- 261.7%
- B/E move
- 6.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.99
- IV
- 311.8%
- B/E move
- 5.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.91
- IV
- 405.8%
- B/E move
- 5.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 217.06% | |
| 200.32% | |
| 224.62% | |
| 223.10% | |
| 225.62% | |
| 228.98% | |
| 202.73% | |
| 215.42% | |
| 210.33% | |
| 144.81% |
Biotechnology
CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →DFTX
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New…
More →DMAC
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis,…
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →